AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12650950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg b.i.d.
Number of subjects: 175
Study 12650950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 12650950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 175
Study 12650950 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg)
Number of subjects: 175
Study 11147930 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine treatment
Number of subjects: 16
Study 8741958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg cocaine
Number of subjects: 0
Study 8741958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg cocaine
Number of subjects: 0
Study 8741958 — intervention group
Group type: COMPARATOR
Intervention: 5.0 mg placebo
Number of subjects: 0
Study 1422928 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 33
Study 1422928 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg
Number of subjects: 33
Study 1422928 — intervention group
Group type: COMPARATOR
Intervention: Diazepam only
Number of subjects: 33
Study 4048254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (X)
Number of subjects: 9
Study 4048254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (Helm)
Number of subjects: 9
Study 30056384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical chest compression device
Number of subjects: 4471
Study 27050475 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention treatment
Number of subjects: 322
Study 27050475 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics (male gender, unemployment, poor premorbid achievement, later age of onset)
Number of subjects: 322
Study 27050475 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms amelioration
Number of subjects: 322
Study 27050475 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom scores
Number of subjects: 322
Study 27050475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests
Number of subjects: 322
Study 25651378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl alone (5 microgram per kilogram)
Number of subjects: 16
Study 25651378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus ketoconazole (200 milligram orally B.I.D. over 2 days)
Number of subjects: 16
Study 25651378 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 16
Study 25651378 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A probe drug)
Number of subjects: 16
Study 23842591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose triiodothyronine (0.5 mcg/kg orally every 24 hr for 3 days)
Number of subjects: 43
Study 23842591 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose triiodothyronine (0.5 mcg/kg orally every 12 hr for 3 days)
Number of subjects: 43
Study 23842591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20702794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate at therapeutic levels (0.4‐0.8 mEq/L)
Number of subjects: 171
Study 20702794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate at subtherapeutic levels (0.2‐0.4 mEq/L)
Number of subjects: 171
Study 20702794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapeutic and subtherapeutic lithium carbonate
Number of subjects: 171
Study 18157835 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (milk thistle extract)
Number of subjects: 1145
Study 18157835 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of silymarin
Number of subjects: 1145
Study 16263254 — intervention group
Group type: EXPERIMENTAL
Intervention: beta(2)-agonist therapy
Number of subjects: 80
Study 14597974 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) at doses ranging from 0.3 to 5 micro g/kg
Number of subjects: 0
Study 14597974 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 14597974 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2)
Number of subjects: 0
Study 14597974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine factor X interaction
Number of subjects: 0
Study 10862388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (Relafen)
Number of subjects: 30
Study 10862388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9276053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (Cryo/Cuff, AirCast, Summit, NJ)
Number of subjects: 15
Study 9276053 — intervention group
Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 15
Study 1486159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine spray 50 mg (Group A)
Number of subjects: 60
Study 1486159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine spray 100 mg (Group B)
Number of subjects: 60
Study 1486159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine spray 200 mg (Group C)
Number of subjects: 60
Study 1486159 — intervention group
Group type: COMPARATOR
Intervention: Control (no lignocaine spray)
Number of subjects: 60
Study 3815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized education
Number of subjects: 82
Study 3815751 — intervention group
Group type: COMPARATOR
Intervention: Control (no specialized education)
Number of subjects: 82
Study 31316254 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw PFN
Number of subjects: 60
Study 31316254 — intervention group
Group type: COMPARATOR
Intervention: Helical PFN
Number of subjects: 60
Study 27868366 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin
Number of subjects: 10
Study 27868366 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 25336730 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA CS
Number of subjects: 30
Study 25336730 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA ME-TRAP
Number of subjects: 30
Study 25336730 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 30
Study 23265758 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel injection approach
Number of subjects: 40
Study 23265758 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection approach
Number of subjects: 40
Study 21764203 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of warfarin without interruption (group 1)
Number of subjects: 40
Study 21764203 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin bridged with low-molecular-weight heparin (group 2)
Number of subjects: 40
Study 21764203 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin bridged with unfractionated heparin (group 3)
Number of subjects: 40
Study 21764203 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy individuals (group 4)
Number of subjects: 40
Study 19295955 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte drink containing 36.2 mmol/L sodium (HNa)
Number of subjects: 13
Study 19295955 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte drink containing 19.9 mmol/L sodium (LNa)
Number of subjects: 13
Study 19295955 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (W)
Number of subjects: 13
Study 19295955 — intervention group
Group type: COMPARATOR
Intervention: Colored and flavored distilled water (PL)
Number of subjects: 13
Study 17077623 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of C-reactive protein (CRP)
Number of subjects: 0
Study 17077623 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO and VEGF levels
Number of subjects: 0
Study 17077623 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP and interleukin-6 levels
Number of subjects: 0
Study 17077623 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO
Number of subjects: 0
Study 14759641 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (ALCAR) 1 g twice daily
Number of subjects: 36
Study 14759641 — intervention group
Group type: COMPARATOR
Intervention: Amantadine 100 mg twice daily
Number of subjects: 36
Study 11455175 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1
Study 11455175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 9447899 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g t.i.d.)
Number of subjects: 151
Study 9447899 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (1 g t.i.d.)
Number of subjects: 151
Study 7639373 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine (10 mL 1%)
Number of subjects: 0
Study 7639373 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial lidocaine (10 mL 1%)
Number of subjects: 0
Study 3358883 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbimide (CC) 50 mg
Number of subjects: 10
Study 3358883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31789541 — intervention group
Group type: EXPERIMENTAL
Intervention: HTUG + IPT
Number of subjects: 52
Study 31789541 — intervention group
Group type: COMPARATOR
Intervention: IPT-Only
Number of subjects: 52
Study 29438682 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum copper concentrations >24 μmol/L
Number of subjects: 408
Study 29438682 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (5th percentile or greater)
Number of subjects: 408
Study 29438682 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum zinc and copper concentrations
Number of subjects: 408
Study 29438682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary zinc intake
Number of subjects: 408
Study 29438682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary copper intake
Number of subjects: 408
Study 29438682 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum copper concentration
Number of subjects: 408
Study 27349410 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds determined from training set using AOD750 inferiorly at 0.31 mm threshold
Number of subjects: 189
Study 27349410 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds determined from training set using TICV500 at 1.92 μL
Number of subjects: 189
Study 27349410 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds determined from training set using TICV750 at 4.00 μL
Number of subjects: 189
Study 25899420 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine-based dressings
Number of subjects: 80
Study 25899420 — intervention group
Group type: COMPARATOR
Intervention: Silver dressings
Number of subjects: 80
Study 24084533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal colpopexy repair with mesh
Number of subjects: 65
Study 24084533 — intervention group
Group type: COMPARATOR
Intervention: Traditional vaginal prolapse surgery without mesh
Number of subjects: 65
Study 21390318 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized cooling protocol
Number of subjects: 15
Study 21390318 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT-positive subjects (n=26)
Number of subjects: 15
Study 18309945 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin with dexrazoxane (n = 105)
Number of subjects: 205
Study 18309945 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone (n = 100)
Number of subjects: 205
Study 17136298 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene antagonists (LTA)
Number of subjects: 0
Study 17136298 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids + long‐acting Beta2 agonists
Number of subjects: 0
Study 17136298 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 12702125 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-based sealer
Number of subjects: 199
Study 12702125 — intervention group
Group type: COMPARATOR
Intervention: Grossman's sealer
Number of subjects: 199
Study 10810776 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcoronary ablation of septum hypertrophy (TASH)
Number of subjects: 187
Study 8821373 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg, single-dose application)
Number of subjects: 16
Study 8821373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1563211 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms as a single dose or q.i.d. as a multiple dose)
Number of subjects: 16
Study 1563211 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg single-dose administration or 50 mg t.i.d. multiple-dose administration)
Number of subjects: 16
Study 6860527 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol 160 mg daily
Number of subjects: 11
Study 6860527 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol 80 mg twice daily
Number of subjects: 11
Study 6860527 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol 160 mg daily
Number of subjects: 11
Study 29807629 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdissociative intravenous-dose ketamine (SDK) at 0.3 mg/kg
Number of subjects: 60
Study 29807629 — intervention group
Group type: COMPARATOR
Intervention: Morphine at 0.1 mg/kg
Number of subjects: 60
Study 29617375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandebereho intervention
Number of subjects: 1199
Study 29617375 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1199
Study 27560168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks)
Number of subjects: 68
Study 27560168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 27560168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 68
Study 24493296 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage treatment (laparoscopic cholecystectomy and CBD exploration at the same operation)
Number of subjects: 221
Study 24493296 — intervention group
Group type: COMPARATOR
Intervention: Two-stage treatment (endoscopic stone clearance followed by laparoscopic cholecystectomy 2-5 days later)
Number of subjects: 221
Study 24493296 — intervention group
Group type: COMPARATOR
Intervention: Two-stage treatment
Number of subjects: 221
Study 24493296 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage treatment
Number of subjects: 221
Study 19261314 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate+sulfadoxine/pyrimethamine (AS+SP) (4 mg/kg AS for 3 consecutive days+25 mg sulfadoxine on Day 0)
Number of subjects: 46
Study 19261314 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (PZQ) (40 mg/kg)
Number of subjects: 46
Study 19261314 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate+sulfadoxine/pyrimethamine (AS+SP)
Number of subjects: 46
Study 19261314 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (PZQ)
Number of subjects: 46
Study 15867120 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based quality improvement intervention (coaching practice staff in auditing performance and implementing new care processes)
Number of subjects: 44
Study 15867120 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 44
Study 15867120 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based quality improvement intervention
Number of subjects: 44
Study 11561925 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about thoughts and feelings regarding coming to college
Number of subjects: 69
Study 11561925 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about a negative personal experience
Number of subjects: 69
Study 11561925 — intervention group
Group type: COMPARATOR
Intervention: Writing about a positive experience
Number of subjects: 69
Study 11561925 — intervention group
Group type: COMPARATOR
Intervention: Writing about a trivial topic
Number of subjects: 69
Study 9853200 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 0
Study 9853200 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 10 mg/day
Number of subjects: 0
Study 7922999 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) with cisplatin (50 mg) mixed with Lipiodol (5-15 ml) and gelfoam pieces.
Number of subjects: 46
Study 7922999 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial embolization (TAE) with Lipiodol and gelfoam pieces only (control group).
Number of subjects: 46
Study 3072223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 5 mg 3 times daily
Number of subjects: 18
Study 3072223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg 3 times daily
Number of subjects: 18
Study 3072223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12501067 — intervention group
Group type: EXPERIMENTAL
Intervention: Active magnets (500 G) applied to abdominal trigger points for 24 hours per day for 4 weeks
Number of subjects: 32
Study 12501067 — intervention group
Group type: COMPARATOR
Intervention: Placebo magnets
Number of subjects: 32
Study 31756716 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training with daily text prompts to practice mindfulness for 10 minutes
Number of subjects: 0
Study 31756716 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a placebo message
Number of subjects: 0
Study 29846278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatment (cooling gel cuff)
Number of subjects: 276
Study 29846278 — intervention group
Group type: COMPARATOR
Intervention: Control (sham control cuff)
Number of subjects: 276
Study 26714233 — intervention group
Group type: EXPERIMENTAL
Intervention: BSAFER Web-based program
Number of subjects: 40
Study 26714233 — intervention group
Group type: COMPARATOR
Intervention: Web-based control program
Number of subjects: 40
Study 24687385 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84) 100 μg/d s.c.
Number of subjects: 62
Study 24687385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22583743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin
Number of subjects: 553
Study 22583743 — intervention group
Group type: COMPARATOR
Intervention: Dry powder device for inhaled tobramycin
Number of subjects: 553
Study 20345956 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation and/or nutritional supplementation
Number of subjects: 116
Study 20345956 — intervention group
Group type: COMPARATOR
Intervention: Stunted group
Number of subjects: 116
Study 20345956 — intervention group
Group type: COMPARATOR
Intervention: Non-stunted group
Number of subjects: 116
Study 20345956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 116
Study 18848176 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring of drug adherence (Medication Event Monitoring System)
Number of subjects: 68
Study 18848176 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 68
Study 15753751 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with active scavenging
Number of subjects: 15
Study 15753751 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane without active scavenging
Number of subjects: 15
Study 12439472 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Orthodontic Treatment Need (IOTN) instruction
Number of subjects: 0
Study 12439472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12439472 — intervention group
Group type: COMPARATOR
Intervention: Sham-control group
Number of subjects: 0
Study 10037249 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment at a daily dose of 0.1 IU/kg (n=26) or 0.2 IU/kg (n=7) body weight
Number of subjects: 33
Study 10037249 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 33
Study 8947323 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hours of cognitive behavioral counseling over 1 year
Number of subjects: 105
Study 8947323 — intervention group
Group type: COMPARATOR
Intervention: Advice to reduce alcohol intake
Number of subjects: 105
Study 2015150 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% isoflurane in oxygen
Number of subjects: 75
Study 2015150 — intervention group
Group type: COMPARATOR
Intervention: Traditional techniques using nitrous oxide and gradually increasing inspired vapour concentration
Number of subjects: 75
Study 7127998 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg b.i.d. for 12 weeks, increased to 0.2 mg for 12 weeks)
Number of subjects: 29
Study 7127998 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (24 mg b.i.d. for 12 weeks, increased to 50 mg for 12 weeks)
Number of subjects: 29
Study 31793688 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer‐Led Asthma Self‐Management Program for Adolescents (PLASMA)
Number of subjects: 259
Study 31793688 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 259
Study 30675742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led telephone follow-up (TFU) intervention
Number of subjects: 0
Study 30506536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training group
Number of subjects: 92
Study 30506536 — intervention group
Group type: COMPARATOR
Intervention: Bladder non-training group
Number of subjects: 92
Study 27176465 — intervention group
Group type: COMPARATOR
Intervention: Price reduction
Number of subjects: 644
Study 27176465 — intervention group
Group type: COMPARATOR
Intervention: Combined skill-building and price reduction
Number of subjects: 644
Study 27176465 — intervention group
Group type: COMPARATOR
Intervention: Skill-building
Number of subjects: 644
Study 27176465 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention
Number of subjects: 644
Study 25133855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 89
Study 25133855 — intervention group
Group type: COMPARATOR
Intervention: Internet-based guided self-help
Number of subjects: 89
Study 25133855 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist adherence
Number of subjects: 89
Study 22243774 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1/oxaliplatin (SOX)
Number of subjects: 129
Study 22243774 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine/oxaliplatin (CAPOX)
Number of subjects: 129